| Title |
Insomnia in Patients with Depression
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/00023210-200923040-00004 |
| Pubmed ID | |
| Authors |
Ripu D. Jindal |
| Abstract |
The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority. However, most antidepressant agents do not adequately address the sleep complaints in depression: their effects on sleep range from sizeable improvement to equally significant worsening. One approach to the management of insomnia associated with depression is to choose a sedating antidepressant agent such as trazodone, mirtazapine or agomelatine. A second approach is to start with a non-sedating antidepressant (e.g. the selective serotonin reuptake inhibitors, bupropion, venlafaxine or duloxetine); those with a persistent or treatment-emergent insomnia can be switched to a more sedating antidepressant, or offered a hypnotic or cognitive-behavioural therapy as adjunctive treatment. The review discusses the advantages and disadvantages of all treatment options, pharmacological and otherwise. |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| India | 1 | 1% |
| Netherlands | 1 | 1% |
| Switzerland | 1 | 1% |
| Unknown | 77 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 12% |
| Student > Master | 10 | 12% |
| Student > Bachelor | 10 | 12% |
| Student > Doctoral Student | 10 | 12% |
| Researcher | 8 | 10% |
| Other | 18 | 22% |
| Unknown | 15 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 35% |
| Psychology | 17 | 21% |
| Agricultural and Biological Sciences | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Nursing and Health Professions | 2 | 2% |
| Other | 7 | 9% |
| Unknown | 20 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2024.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from CNS Drugs
#768
of 1,388 outputs
Outputs of similar age
#64,269
of 187,955 outputs
Outputs of similar age from CNS Drugs
#275
of 541 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.